Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease

Introduction: Currently, available therapies for Parkinson’s disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS...

Descripción completa

Detalles Bibliográficos
Autores: Pérez Lloret, Santiago, Otero-Losada, Matilde Estela, Toblli, Jorge Eduardo, Capani, Francisco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/41832
Acceso en línea:http://hdl.handle.net/11336/41832
Access Level:acceso abierto
Palabra clave:Parkinson Disease
Angiotensin
Neuroprotection
Renin
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
id AR_8d14280deefea53a0ef90a2d5ef899b7
oai_identifier_str oai:ri.conicet.gov.ar:11336/41832
network_acronym_str AR
network_name_str Argentina
repository_id_str
dc.title.none.fl_str_mv Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
title Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
spellingShingle Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
Pérez Lloret, Santiago
Parkinson Disease
Angiotensin
Neuroprotection
Renin
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
title_short Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
title_full Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
title_fullStr Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
title_full_unstemmed Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
title_sort Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
dc.creator.none.fl_str_mv Pérez Lloret, Santiago
Otero-Losada, Matilde Estela
Toblli, Jorge Eduardo
Capani, Francisco
author Pérez Lloret, Santiago
author_facet Pérez Lloret, Santiago
Otero-Losada, Matilde Estela
Toblli, Jorge Eduardo
Capani, Francisco
author_role author
author2 Otero-Losada, Matilde Estela
Toblli, Jorge Eduardo
Capani, Francisco
author2_role author
author
author
dc.subject.none.fl_str_mv Parkinson Disease
Angiotensin
Neuroprotection
Renin
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
topic Parkinson Disease
Angiotensin
Neuroprotection
Renin
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
description Introduction: Currently, available therapies for Parkinson’s disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability. Neuroprotective effects in animal PD models have been shown for the angiotensin-converting enzyme (ACE) inhibitors captopril and perindopril, and the AT1 receptor antagonists losartan, candesartan and telmisartan. These effects appear to be mediated by a reduction in the overproduction of reactive oxygen species. In a proof-of-concept, randomized, double-blind, crossover study in PD patients, perindopril enhanced the effect of levodopa without inducing dyskinesias. There has not been any clinical trial exploring the neuroprotective effect of RAS drugs, but one cohort study in hypertensive patients suggested a protective effect of ACE inhibitors on PD risk. RAS is a promising target for symptomatic and neuroprotective therapies in PD. Further studies in PD animal models and patients are warranted.
publishDate 2017
dc.date.none.fl_str_mv 2017-08
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/41832
Pérez Lloret, Santiago; Otero-Losada, Matilde Estela; Toblli, Jorge Eduardo; Capani, Francisco; Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease; Informa Healthcare; Expert Opinion on Investigational Drugs; 26; 10; 8-2017; 1163-1173
1354-3784
CONICET Digital
CONICET
url http://hdl.handle.net/11336/41832
identifier_str_mv Pérez Lloret, Santiago; Otero-Losada, Matilde Estela; Toblli, Jorge Eduardo; Capani, Francisco; Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease; Informa Healthcare; Expert Opinion on Investigational Drugs; 26; 10; 8-2017; 1163-1173
1354-3784
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1080/13543784.2017.1371133
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1080/13543784.2017.1371133
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799195607257055232
spelling Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s diseasePérez Lloret, SantiagoOtero-Losada, Matilde EstelaToblli, Jorge EduardoCapani, FranciscoParkinson DiseaseAngiotensinNeuroprotectionReninhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Introduction: Currently, available therapies for Parkinson’s disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability. Neuroprotective effects in animal PD models have been shown for the angiotensin-converting enzyme (ACE) inhibitors captopril and perindopril, and the AT1 receptor antagonists losartan, candesartan and telmisartan. These effects appear to be mediated by a reduction in the overproduction of reactive oxygen species. In a proof-of-concept, randomized, double-blind, crossover study in PD patients, perindopril enhanced the effect of levodopa without inducing dyskinesias. There has not been any clinical trial exploring the neuroprotective effect of RAS drugs, but one cohort study in hypertensive patients suggested a protective effect of ACE inhibitors on PD risk. RAS is a promising target for symptomatic and neuroprotective therapies in PD. Further studies in PD animal models and patients are warranted.Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaFil: Otero-Losada, Matilde Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaFil: Toblli, Jorge Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaFil: Capani, Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaInforma Healthcare2017-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/41832Pérez Lloret, Santiago; Otero-Losada, Matilde Estela; Toblli, Jorge Eduardo; Capani, Francisco; Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease; Informa Healthcare; Expert Opinion on Investigational Drugs; 26; 10; 8-2017; 1163-11731354-3784CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1080/13543784.2017.1371133info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/abs/10.1080/13543784.2017.1371133info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T13:57:51Zoai:ri.conicet.gov.ar:11336/41832instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 13:57:51.484CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
score 15,811543

Similares en LA Referencia